Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase 3 randomised controlled trial (Q102059782)
Jump to navigation
Jump to search
scientific article published on 11 November 2020
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase 3 randomised controlled trial |
scientific article published on 11 November 2020 |
Statements
Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase 3 randomised controlled trial (English)
B Xu
T Sun
Q Zhang
P Zhang
Z Yuan
Z Jiang
X Wang
S Cui
Y Teng
X-C Hu
J Yang
H Pan
Z Tong
H Li
Q Yao
Y Wang
Y Yin
P Sun
H Zheng
J Cheng
J Lu
B Zhang
C Geng
J Liu
K Shen
S Yu
H Li
L Tang
R Qiu
study group of BG01-1323L
11 November 2020